Effective cooperation of monoclonal antibody and peptide vaccine for the treatment of mouse melanoma

Journal of Immunology

Volumn 190, Issue 1, 2013, Pages 489-496

  Ly, Long V ^a   Sluijter, Marjolein ^a   Van Der Burg, Sjoerd H ^a   Jager, Martine J ^a   Van Hall, Thorbald ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALANYLVALYLGLYCYLALANYLLEUCYLGLUTAMYLGLYCYLPROLYLARGINYLASPARAGINYLGLUTAMINYLASPARTYLTRYPTOPHYLLEUCYLGLYCYLVALYLPROLYLARGINYLGLUTAMINYLLEUCINE VACCINE; ALANYLVALYLGLYCYLALANYLLEUCYLGLUTAMYLGLYCYLSERYLARGINYLASPARAGINYLGLUTAMINYLASPARTYLTRYPTOPHYLLEUCYLGLYCYLVALYLPROLYLARGINYLGLUTAMINYLLEUCINE VACCINE; COMPLEMENT COMPONENT C3; FC RECEPTOR; GLUTAMYLGLYCYLPROLYLARGINYLASPARAGINYLGLUTAMINYLASPARTYLTRYPTOPHYLLEUCINE VACCINE; GLUTAMYLGLYCYLSERYLARGINYLASPARAGINYLGLUTAMINYLASPARTYLTRYPTOPHYLLEUCINE VACCINE; GLYCOPROTEIN GP 100; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TA99; PEPTIDE VACCINE; RECOMBINANT GAMMA INTERFERON[175-193] VACCINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; CANCER CONTROL; CANCER TISSUE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CUTANEOUS MELANOMA; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; ERADICATION THERAPY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INNATE IMMUNITY; MELANOMA B16F10; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; TRANSPLANTABLE SOLID TUMORS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN PRESENTATION; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL LINE, TUMOR; COCULTURE TECHNIQUES; DRUG THERAPY, COMBINATION; EPITOPES, T-LYMPHOCYTE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; SKIN NEOPLASMS; VACCINES, SUBUNIT;

EID: 84871845163     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1200135     Document Type: Article

References (49)

1. Weiner, L. M., M. V. Dhodapkar, and S. Ferrone. 2009. Monoclonal antibodies for cancer immunotherapy. Lancet 373: 1033-1040.
2. Campoli, M., R. Ferris, S. Ferrone, and X. Wang. 2010. Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies. Clin. Cancer Res. 16: 11-20.
3. Ferris, R. L., E. M. Jaffee, and S. Ferrone. 2010. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J. Clin. Oncol. 28: 4390-4399.
4. Schuurhuis, D. H., N. van Montfoort, A. Ioan-Facsinay, R. Jiawan, M. Camps, J. Nouta, C. J. Melief, J. S. Verbeek, and F. Ossendorp. 2006. Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine. J. Immunol. 176: 4573-4580.
5. Wolpoe, M. E., E. R. Lutz, A. M. Ercolini, S. Murata, S. E. Ivie, E. S. Garrett, L. A. Emens, E. M. Jaffee, and R. T. Reilly. 2003. HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice. J. Immunol. 171: 2161-2169. (Pubitemid 36966500)
6. Harbers, S. O., A. Crocker, G. Catalano, V. D'Agati, S. Jung, D. D. Desai, and R. Clynes. 2007. Antibody-enhanced cross-presentation of self antigen breaks T cell tolerance. J. Clin. Invest. 117: 1361-1369. (Pubitemid 46718424)
7. Taylor, C., D. Hershman, N. Shah, N. Suciu-Foca, D. P. Petrylak, R. Taub, L. Vahdat, B. Cheng, M. Pegram, K. L. Knutson, and R. Clynes. 2007. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin. Cancer Res. 13: 5133-5143. (Pubitemid 47502081)
8. Saenger, Y. M., Y. Li, K. C. Chiou, B. Chan, G. Rizzuto, S. L. Terzulli, T. Merghoub, A. N. Houghton, and J. D. Wolchok. 2008. Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma. Cancer Res. 68: 9884-9891.
9. van Montfoort, N., S. M. Mangsbo, M. G. Camps, W. W. van Maren, I. E. Verhaart, A. Waisman, J. W. Drijfhout, C. J. Melief, J. S. Verbeek, and F. Ossendorp. 2012. Circulating specific antibodies enhance systemic cross-priming by delivery of complexed antigen to dendritic cells in vivo. Eur. J. Immunol. 42: 598-606.
10. Drake, C. G. 2010. Prostate cancer as a model for tumour immunotherapy. Nat. Rev. Immunol. 10: 580-593.
11. Mellman, I., G. Coukos, and G. Dranoff. 2011. Cancer immunotherapy comes of age. Nature 480: 480-489.
12. Rosenberg, S. A., J. C. Yang, and N. P. Restifo. 2004. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10: 909-915. (Pubitemid 39273730)
13. Kenter, G. G., M. J. Welters, A. R. Valentijn, M. J. Lowik, D. M. Berends-van der Meer, A. P. Vloon, F. Essahsah, L. M. Fathers, R. Offringa, J. W. Drijfhout, et al. 2009. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 361: 1838-1847.
14. Zwaveling, S., S. C. Ferreira Mota, J. Nouta, M. Johnson, G. B. Lipford, R. Offringa, S. H. van der Burg, and C. J. Melief. 2002. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J. Immunol. 169: 350-358. (Pubitemid 34686155)
15. Bijker, M. S., S. J. van den Eeden, K. L. Franken, C. J. Melief, R. Offringa, and S. H. van der Burg. 2007. CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J. Immunol. 179: 5033-5040.
16. Bijker, M. S., S. J. van den Eeden, K. L. Franken, C. J. Melief, S. H. van der Burg, and R. Offringa. 2008. Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation. Eur. J. Immunol. 38: 1033-1042.
17. van Hall, T., and S. H. van der Burg. 2012. Mechanisms of peptide vaccination in mouse models: tolerance, immunity, and hyperreactivity. Adv. Immunol. 114: 51-76.
18. Klein, L., M. Hinterberger, G. Wirnsberger, and B. Kyewski. 2009. Antigen presentation in the thymus for positive selection and central tolerance induction. Nat. Rev. Immunol. 9: 833-844.
19. Koble, C., and B. Kyewski. 2009. The thymic medulla: a unique microenvironment for intercellular self-antigen transfer. J. Exp. Med. 206: 1505-1513.
20. Carpenter, A. C., and R. Bosselut. 2010. Decision checkpoints in the thymus. Nat. Immunol. 11: 666-673.
21. van Stipdonk, M. J., D. Badia-Martinez, M. Sluijter, R. Offringa, T. van Hall, and A. Achour. 2009. Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-associated epitope gp100. Cancer Res. 69: 7784-7792.
22. Overwijk, W. W., A. Tsung, K. R. Irvine, M. R. Parkhurst, T. J. Goletz, K. Tsung, M. W. Carroll, C. Liu, B. Moss, S. A. Rosenberg, and N. P. Restifo. 1998. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 188: 277-286. (Pubitemid 28357756)
23. Schreurs, M. W., A. A. Eggert, A. J. de Boer, J. L. Vissers, T. van Hall, R. Offringa, C. G. Figdor, and G. J. Adema. 2000. Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model. Cancer Res. 60: 6995-7001. (Pubitemid 32059175)
24. Guevara-Patiño, J. A., M. E. Engelhorn, M. J. Turk, C. Liu, F. Duan, G. Rizzuto, A. D. Cohen, T. Merghoub, J. D. Wolchok, and A. N. Houghton. 2006. Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. J. Clin. Invest. 116: 1382-1390.
25. Ly, L. V., M. Sluijter, M. Versluis, G. P. Luyten, M. J. van Stipdonk, S. H. van der Burg, C. J. Melief, M. J. Jager, and T. van Hall. 2010. Peptide vaccination after T-cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm. [Published erratum appears in 2011 Cancer Res. 71: 4048.] Cancer Res. 70: 8339-8346.
26. Rechtsteiner, G., T. Warger, P. Osterloh, H. Schild, and M. P. Radsak. 2005. Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod. J. Immunol. 174: 2476-2480. (Pubitemid 40279657)
27. Adams, S., D. W. O'Neill, D. Nonaka, E. Hardin, L. Chiriboga, K. Siu, C. M. Cruz, A. Angiulli, F. Angiulli, E. Ritter, et al. 2008. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J. Immunol. 181: 776-784.
28. Takechi, Y., I. Hara, C. Naftzger, Y. Xu, and A. N. Houghton. 1996. A melanosomal membrane protein is a cell surface target for melanoma therapy. Clin. Cancer Res. 2: 1837-1842. (Pubitemid 26384150)
29. van Spriel, A. B., H. H. van Ojik, A. Bakker, M. J. Jansen, and J. G. van de Winkel. 2003. Mac-1 (CD11b/CD18) is crucial for effective Fc receptor-mediated immunity to melanoma. Blood 101: 253-258. (Pubitemid 36025915)
30. Bevaart, L., M. J. Jansen, M. J. van Vugt, J. S. Verbeek, J. G. van de Winkel, and J. H. Leusen. 2006. The high-affinity IgG receptor, FcgammaRI, plays a central role in antibody therapy of experimental melanoma. Cancer Res. 66: 1261-1264. (Pubitemid 43259901)
31. Otten, M. A., G. J. van der Bij, S. J. Verbeek, F. Nimmerjahn, J. V. Ravetch, R. H. Beelen, J. G. van de Winkel, and M. van Egmond. 2008. Experimental antibody therapy of liver metastases reveals functional redundancy between Fc gammaRI and Fc gammaRIV. J. Immunol. 181: 6829-6836.
32. Markiewski, M. M., R. A. DeAngelis, F. Benencia, S. K. Ricklin-Lichtsteiner, A. Koutoulaki, C. Gerard, G. Coukos, and J. D. Lambris. 2008. Modulation of the antitumor immune response by complement. Nat. Immunol. 9: 1225-1235.
33. van der Bij, G. J., M. Bögels, M. A. Otten, S. J. Oosterling, P. J. Kuppen, S. Meijer, R. H. Beelen, and M. van Egmond. 2010. Experimentally induced liver metastases from colorectal cancer can be prevented by mononuclear phagocyte-mediated monoclonal antibody therapy. J. Hepatol. 53: 677-685.
34. Biburger, M., S. Aschermann, I. Schwab, A. Lux, H. Albert, H. Danzer, M. Woigk, D. Dudziak, and F. Nimmerjahn. 2011. Monocyte subsets responsible for immunoglobulin G-dependent effector functions in vivo. Immunity 35: 932-944.
35. Ly, L. V., A. Baghat, M. Versluis, E. S. Jordanova, G. P. Luyten, N. van Rooijen, T. van Hall, P. A. van der Velden, and M. J. Jager. 2010. In aged mice, outgrowth of intraocular melanoma depends on proangiogenic M2-type macrophages. J. Immunol. 185: 3481-3488.
36. Allavena, P., A. Sica, C. Garlanda, and A. Mantovani. 2008. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol. Rev. 222: 155-161. (Pubitemid 351430369)
37. Mantovani, A., and A. Sica. 2010. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr. Opin. Immunol. 22: 231-237.
38. Sutmuller, R. P., L. M. van Duivenvoorde, A. van Elsas, T. N. Schumacher, M. E. Wildenberg, J. P. Allison, R. E. Toes, R. Offringa, and C. J. Melief. 2001. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194: 823-832. (Pubitemid 32983017)
39. Overwijk, W. W. 2005. Breaking tolerance in cancer immunotherapy: time to ACT. Curr. Opin. Immunol. 17: 187-194. (Pubitemid 40343107)
40. Rosenberg, S. A., and M. E. Dudley. 2009. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr. Opin. Immunol. 21: 233-240.
41. Sikora, A. G., N. Jaffarzad, Y. Hailemichael, A. Gelbard, S. W. Stonier, K. S. Schluns, L. Frasca, Y. Lou, C. Liu, H. A. Andersson, et al. 2009. IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity. J. Immunol. 182: 7398-7407.
42. Cho, H. I., E. Reyes-Vargas, J. C. Delgado, and E. Celis. 2012. A potent vaccination strategy that circumvents lymphodepletion for effective antitumor adoptive T-cell therapy. Cancer Res. 72: 1986-1995.
43. Melief, C. J., and S. H. van der Burg. 2008. Immunotherapy of established (pre) malignant disease by synthetic long peptide vaccines. Nat. Rev. Cancer 8: 351-360. (Pubitemid 351589701)
44. Castle, J. C., S. Kreiter, J. Diekmann, M. Löwer, N. van de Roemer, J. de Graaf, A. Selmi, M. Diken, S. Boegel, C. Paret, et al. 2012. Exploiting the mutanome for tumor vaccination. Cancer Res. 72: 1081-1091.
45. Sevko, A., V. Kremer, C. Falk, L. Umansky, M. R. Shurin, G. V. Shurin, and V. Umansky. 2012. Application of paclitaxel in low non-cytotoxic doses supports vaccination with melanoma antigens in normal mice. J. Immunotoxicol. 9: 275-281.
46. Cho, H. I., and E. Celis. 2009. Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects. Cancer Res. 69: 9012-9019.
47. Sin, J. I., J. B. Park, I. H. Lee, D. Park, Y. S. Choi, J. Choe, and E. Celis. 2012. Intratumoral electroporation of IL-12 cDNA eradicates established melanomas by Trp2(180-188)-specific CD8+ CTLs in a perforin/granzyme-mediated and IFN-γ-dependent manner: application of Trp2(180-188) peptides. Cancer Immunol. Immunother. 61: 1671-1682.
48. Chapman, P. B. 2004. T-cell chauvinists versus antibody advocates - can't we all just get along? J. Clin. Oncol. 22: 4446-4448. (Pubitemid 41185108)
49. King, D. M., M. R. Albertini, H. Schalch, J. A. Hank, J. Gan, J. Surfus, D. Mahvi, J. H. Schiller, T. Warner, K. Kim, et al. 2004. Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. J. Clin. Oncol. 22: 4463-4473. (Pubitemid 41185112)